Leerink Partners Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $35
Maintained Buy Rating on Myriad Genetics Amid GeneSight Study Discontinuation
Jefferies Upgrades Myriad Genetics(MYGN.US) to Buy Rating, Raises Target Price to $35
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Raises Target Price to $34
Scotiabank Remains a Buy on Myriad Genetics (MYGN)
Myriad Genetics Analyst Ratings
Myriad Genetics Price Target Raised to $30.00/Share From $28.00 by TD Cowen
Myriad Genetics Analyst Ratings
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
TD Cowen Keeps Their Hold Rating on Myriad Genetics (MYGN)
Myriad Genetics Analyst Ratings
Myriad Genetics Analyst Ratings
Myriad Genetics Analyst Ratings
Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics Analyst Ratings
Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35
Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty
Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)